Heme Arginate

Summary

Heme Arginate (CHEMBL4297285) is a phase-3 clinical-stage small molecule; indicated across 5 conditions including acute kidney injury and ischemia reperfusion injury.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Indications: 5 conditions
• Clinical trials: 10

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4297285
Name	Heme Arginate
Type	Small molecule
Max phase	3

Also known as: Haem arginate, Heme arginate, HEME ARGINATE

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

5 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
acute kidney injury	2	MONDO:0002492	HP:0001919
ischemia reperfusion injury	2	MONDO:0005203	EFO:0002687
myocardial ischemia	2	MONDO:0024644	EFO:1001375
porphyria	2	MONDO:0037939	MONDO:0037939
acute myocardial infarction	1	MONDO:0004781	EFO:0008583

Clinical trials

Total trials: 10.

Phase distribution

Phase	Trials
PHASE2	3
PHASE1	3
PHASE1/PHASE2	2
PHASE4	1
PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00856817	PHASE4	TERMINATED	Heme Oxygenase (HO) Activity and Adenosine Induced Vasodilation
NCT03646344	PHASE3	TERMINATED	Heme Arginate in Transplantation Study
NCT00004396	PHASE2	COMPLETED	Studies in Porphyria III: Heme and Tin Mesoporphyrin in Acute Porphyrias
NCT00004789	PHASE1/PHASE2	COMPLETED	Phase I/II Study of Heme Arginate and Tin Mesoporphyrin for Acute Porphyria
NCT00483587	PHASE1/PHASE2	COMPLETED	Does Heme Oxygenase-1 Induction Ameliorate Cardiac Injury After Myocardial Infarction?
NCT02142699	PHASE2	COMPLETED	Heme Arginate in Cardiac Surgery Patients
NCT02314780	PHASE2	COMPLETED	The Effects of Intravenous Heme Arginate on Heme Oxygenase-1 Expression (HO-1) and Oxidative Stress in the Human Heart
NCT00004397	PHASE1	COMPLETED	Phase I Study of Tin Mesoporphyrin in Patients on Long Term Heme Therapy for Prevention of Acute Attacks of Porphyria
NCT00004398	PHASE1	COMPLETED	Phase I Study of Heme Arginate With or Without Tin Mesoporphyrin in Patients With Acute Attacks of Porphyria
NCT00682370	PHASE1	COMPLETED	Effects of Heme Arginate in Healthy Male Subjects

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).